Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key Tovaxin® data at the upcoming American Academy of Neurology (AAN) 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

Clyde Markowitz, M.D., director of the Multiple Sclerosis Center at the University of Pennsylvania, professor of neurology at the University of Pennsylvania School of Medicine in Philadelphia and member of Opexa's Scientific Advisory Board, will present data from the Phase IIb TERMS clinical trial which demonstrated promising efficacy and safety data in MS patients treated with Tovaxin who were naïve to previous disease modifying therapy.

The data will be presented during a poster session on Thursday, April 14, 2011 from 5:00 to 6:30 p.m. at Poster Session P07, located at P07.192 in the poster hall under the following title: Autologous T-Cell Immunotherapy (Tovaxin) in Treatment-Naïve Patients with Active Relapsing-Remitting Multiple Sclerosis.

Established in 1948, the American Academy of Neurology is an international professional association of more than 22,500 neurologists and neuroscience professionals. The 63rd Annual Meeting will be held in Honolulu, April 9 to April 16, 2011, and will highlight the latest in neurologic research through over 2,000 scientific research presentations. More than 10,000 people are expected to attend the meeting this year.


Opexa Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
CAR T therapy extends its reach beyond oncology